PD Dr. Thomas Wirth
Thomas Wirth is a Principal Investigator in SP12 and one of two equity officers of the RTG 2978.
His research focus lies on cancer immunotherapy, T-Cell vaccines, preclinical cancer models, and T-Cell immunology in infectious disease.
Dr. Wirth was member of the Scientific Committee of the UEG from 2017 to 2021 and since 2019 has been a mentor of the Hannover Biomedical Research School (HBRS) for Molecular Medicine.
| Year | Position |
|---|---|
| 2015 | Board Certification Internal Medicine and Gastroenterology |
| 2015 | Habilitation and Venia legendi in Experimental Gastroenterology |
| 2012 | Dr. med. (“summa cum laude”), supervisor: Prof. Dr. med. Stefan Kubicka, Medical School Hannover |
| Since 2010 | Research group leader, Department of Gastroenterology, Hepatology and Endocrinology, MHH |
| 2006-2009 | Postdoctoral Fellow, Laboratory of John Harty, Department of Microbiology, University of Iowa, Iowa City, US |
| 2005 | Full “Approbation” as Physician |
| 2005 | MD Thesis ("A telomerase-dependent conditionally replicating adenovirus for selective treatment of cancer", summa cum laude) |
| 1999-2004 | MD PhD Thesis, supervisor: Prof. Dr. med. Stefan Kubicka, Department of Gastroenterology, Hepatology and Endocrinology, MHH |
| 1997-2004 | Studies of Human Medicine, University of Greifswald and Hannover Medical School |